Gating of the HypoPP-1 mutations: II. Effects of a calcium-channel agonist BayK 8644

Pflugers Arch. 2007 Jul;454(4):605-14. doi: 10.1007/s00424-007-0228-0. Epub 2007 Mar 1.

Abstract

L-type calcium-channel mutations causing hypokalemic periodic paralysis type 1 (HypoPP-1) have pronounced "loss-of-function" features and stabilize the less-selective second open state O(2), as we demonstrated in the companion paper. Here, we compared the effects of the L-type calcium-channel activator (+/-)BayK 8644 (BayK) on the heterologously expressed wild-type (WT) calcium channel, rabbit Cav1.2 HypoPP-1 analogs, and two double mutants (R650H/R1362H, R650H/R1362G). Our goal was to elucidate (1) whether the "loss-of-function" in HypoPP-1 can be compensated by BayK application, (2) how the less-selective open state is affected by BayK in WT and HypoPP-1 mutants, as well as (3) to gain an insight into BayK mechanism of action. Ionic currents were examined by whole-cell patch-clamp and analyzed by the global-fitting procedure. Our results imply that (1) BayK promotes channel activation, but equalized the differences among the WT and mutants, thus attenuating HypoPP-related effects on activation and deactivation; (2) BayK binds to the first open state O(1), and then serves as a catalyst for O(2) formation; (3) binding of BayK is impaired in the HypoPP mutants, thus affecting the formation of the less-selective second open state; (4) BayK affects cooperativity between the single HypoPP-1 mutations at all stages of the channel gating; and (5) BayK favoring of O(2) lowers calcium-channel selectivity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / pharmacology*
  • Calcium Channel Agonists / pharmacology*
  • Calcium Channels, L-Type / drug effects
  • Calcium Channels, L-Type / genetics*
  • Calcium Channels, L-Type / physiology
  • Cell Line
  • Humans
  • Hypokalemic Periodic Paralysis / genetics*
  • Hypokalemic Periodic Paralysis / physiopathology
  • Ion Channel Gating / drug effects*
  • Ion Channel Gating / physiology
  • Oxygen / metabolism
  • Patch-Clamp Techniques

Substances

  • Calcium Channel Agonists
  • Calcium Channels, L-Type
  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
  • Oxygen